Figure 4. (A) (B) Region of interest (ROI) analysis of the PET
images. The values are presented as the SUVmax (n = 3). (C) Correlation analysis between the SUVmax and CD146 expression.(D) Ex vivo biodistributions of the A375 and A549 cell models
(n = 3/group). *, p < 0.05; **, p <
0.01; ***, p < 0.001; ****, p <
0.0001.
To further evaluate the specific imaging ability of89Zr-IP150 for melanoma, 18F-FDG,
the most commonly used PET imaging tracer in the clinic, was used as a
control. No significant difference in radioactive concentration was
detected between the A375 and HMVII tumors at 1 h p.i., and18F-FDG accumulated mainly in metabolic organs such as
the heart and kidneys (Figure 5A). The uptake of18F-FDG in tumors was significantly lower than that of89Zr-IP150 in both the A375 (0.96±0.06 vs. 5.57±0.29)
and HMVII (1.28±0.03 vs. 7.11±0.08) models (p <0.001)
(Figure 5B). In addition, the tumor/muscle ratio of18F-FDG was also significantly lower than that of89Zr-IP150 (0.96±0.06 vs. 21.48±4.40 in A375 and
2.12±0.06 vs. 21.33±3.45 in HMVII) (Figure 5C) (p<0.0001).